Investors & News / Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit Read more about Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer Read more about Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Read more about Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Read more about Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Read more about Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 Read more about Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 Exelixis Announces Update on Patent Litigation with MSN Laboratories Read more about Exelixis Announces Update on Patent Litigation with MSN Laboratories Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 Read more about Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last » Subscribe to Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit Read more about Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer Read more about Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Read more about Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Read more about Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Read more about Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 Read more about Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
Exelixis Announces Update on Patent Litigation with MSN Laboratories Read more about Exelixis Announces Update on Patent Litigation with MSN Laboratories
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 Read more about Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023